Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): An open-label, randomised, phase 3 trial

The Lancet Oncology

Volumn 16, Issue 6, 2015, Pages 656-666

  Earl, Helena M ^a,b   Hiller, Louise ^c   Dunn, Janet A ^c   Blenkinsop, Clare ^c   Grybowicz, Louise ^d   Vallier, Anne Laure ^d   Abraham, Jean ^a,b,d   Thomas, Jeremy ^e   Provenzano, Elena ^b,d   Hughes Davies, Luke ^d   Gounaris, Ioannis ^d,m   McAdam, Karen ^f   Chan, Stephen ^g   Ahmad, Rizvana ^h   Hickish, Tamas ⁱ   Houston, Stephen ^j   Rea, Daniel ^k   Bartlett, John ^e,l   Caldas, Carlos ^a,b,m   Cameron, David A ^e   Hayward, Larry ^e   Henderson, I Craig ⁿ   Gianni, Luca ^o   Brady, Mark F ^p   Pivot, Xavier ^q   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b and Cambridge Breast Cancer Research Unit Cambridge ^*  (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e WESTERN GENERAL HOSPITAL   (United Kingdom)

^f PETERBOROUGH CITY HOSPITAL   (United Kingdom)

^g NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^h WEST MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

ⁱ BOURNEMOUTH UNIVERSITY   (United Kingdom)

^j ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^k CITY HOSPITAL   (United Kingdom)

^l ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^m CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o SAN RAFFAELE HOSPITAL   (Italy)

^p ROSWELL PARK CANCER INSTITUTE   (United States)

^q UNIVERSITY HOSPITAL OF BESANÇON   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TAXOID;

ADULT; ALLERGIC REACTION; ALOPECIA; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY CANCER; FATIGUE; FEMALE; HUMAN; HYPERTENSION; INFECTION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED KINGDOM; VOMITING; ADJUVANT THERAPY; AGED; BREAST NEOPLASMS; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; LYMPH NODE; PATHOLOGY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; LYMPH NODES; MIDDLE AGED; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2; TAXOIDS;

EID: 84930273565     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)70137-3     Document Type: Article

References (33)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015, 136:E359-E386.
2. Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet 2012, 379:432-444. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
3. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
4. Coombes RC, Bliss JM, Wils J, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol 1996, 14:35-45.
5. Levine MN, Bramwell VH, Pritchard KI, et al. Randomised trial of intensive cyclophosphamide, epirubicin, and fluorouracil compared with cyclophosphamide, methotrexate and fluorouracil in pre-menopausal women with node-positive breast cancer. J Clin Oncol 1998, 16:2651-2658.
6. Poole CJ, Earl HM, Hiller L, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 1996, 355:1851-1862.
7. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003, 21:976-983.
8. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005, 23:3686-3696.
9. Roché H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006, 24:5664-5671.
10. Earl HM Reporting of adjuvant breast cancer trials-when is the right time?. J Clin Oncol 2012, 30:1-2.
11. Earl HM, Vallier A-L, Hiller L, et al. Effect of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial. Lancet Oncol 2014, 15:201-212.
12. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
13. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010, 28:3239-3247.
14. Poole CJ, Hiller L, Howard HC, et al. tAnGo: a randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early stage breast can-cer (EBC). Proc Am Soc Clin Oncol 2008, 26(suppl). abstract 506.
15. Petit T, Wilt M, Velten M, et al. Semiquantitative evaluation of estrogen-receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer. Breast Cancer Res Treat 2010, 124:387-391.
16. Symmans WF, Wei C, Gould R, et al. Long-term prognostic value of residual cancer burden (RCB) classification following neoadjuvant chemotherapy. San Antonio Breast Cancer Symposium. Cancer Res 2013, 73. oral abstract S6-02.
17. Earl HM, Hiller L, Dunn JA, et al. NEAT: National Epirubicin Adjuvant Trial-toxicity, delivered dose intensity and quality of life. Br J Cancer 2008, 99:1226-1231.
18. Miles DW, Dieras V, Cortes J, et al. First-line bevacizumab in combination with chemotherapy for HER2-negtaive metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 2013, 24:2773-2780.
19. von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012, 366:299-309.
20. Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015, 33:13-21.
21. Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012, 366:310-320.
22. Montero AJ, Vogel C Fighting fire with fire: rekindling the bevacizumab debate. N Engl J Med 2012, 366:374-375.
23. Gerber B, Loibl S, Eidtmann H, et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol 2013, 24:2978-2984.
24. von Minckwitz G, Loibl S, Untch M, et al. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†. Ann Oncol 2014, 25:2363-2372.
25. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011, 365:2484-2496.
26. Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 2013, 14:933-942.
27. Miller K, O'Neill AM, Dang CT, et al. Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: final results from Eastern Cooperative Oncology Group E5103. Proc Am Soc Clin Oncol 2014, 32(suppl). abstract 500.
28. Bear HD, Tang G, Rastogi P, et al. The effect on overall and disease-free survival (OS & DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40. San Antonio Breast Cancer Symposium 2014, Poster Discussion, Session 2, Abstract 1.
29. Hatzis C, Gould RE, Zhang Y, et al. Predicting improvements in survival based on improvements in pathologic response rate to neoadjuvant chemotherapy in different breast cancer subtypes. San Antonio Breast Cancer Symposium. Cancer Res 2013, 73. abstract P6-06-37.
30. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014, 384:164-172.
31. Berruti A, Amoroso V, Gallo F, et al. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. J Clin Oncol 2014, 32:3883-3891.
32. Prowell TM, Pazdur R Perspective: pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012, 366:2438-2441.
33. Gourley C, McCavigan A, Perren T, et al. Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. Proc Am Soc Clin Oncol 2014, 32(suppl). abstract 5502.